Therefore, further prospective studies are needed to clarify the therapeutic impact of ACE inhibitors or AT1R antagonists, particularly in combination with approved antifibrotic agents, on clinical outcomes in PF. The gene discussed is AGTR1; the disease is pemphigus foliaceus.